Dimitrios Kioroglou, Rubén Gil-Redondo, Nieves Embade, Maider Bizkarguenaga, Ricardo Conde, Oscar Millet, José M Mato, Urko M Marigorta
{"title":"多基因组整合为健康个体的早期预防战略奠定了基础。","authors":"Dimitrios Kioroglou, Rubén Gil-Redondo, Nieves Embade, Maider Bizkarguenaga, Ricardo Conde, Oscar Millet, José M Mato, Urko M Marigorta","doi":"10.1038/s41525-025-00491-7","DOIUrl":null,"url":null,"abstract":"<p><p>Precision medicine requires biomarkers that stratify patients and improve clinical outcomes. Although longitudinal multi-omic analyses provide insights into pathological states, their utility in stratifying healthy individuals remains underexplored. We performed a cross-sectional integrative study of three omic layers, including genomics, urine metabolomics, and serum metabolomics/lipoproteomics, on a cohort of 162 individuals without pathological manifestations. We studied each omic layer separately and after integration, concluding that multi-omic integration provides optimal stratification capacity. We identified four subgroups and, for a subset of 61 individuals, longitudinal data for two additional time-points allowed us to evaluate the temporal stability of the molecular profiles of each identified subgroup. Additional functional annotation uncovered accumulation of risk factors associated with dyslipoproteinemias in one subgroup, suggesting targeted monitoring could reduce future cardiovascular risks. Overall, our methodology uncovers the potential of multi-omic profiling to serve as a framework for precision medicine aimed at early prevention strategies.</p>","PeriodicalId":19273,"journal":{"name":"NPJ Genomic Medicine","volume":"10 1","pages":"35"},"PeriodicalIF":4.7000,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12049560/pdf/","citationCount":"0","resultStr":"{\"title\":\"Multi-omic integration sets the path for early prevention strategies on healthy individuals.\",\"authors\":\"Dimitrios Kioroglou, Rubén Gil-Redondo, Nieves Embade, Maider Bizkarguenaga, Ricardo Conde, Oscar Millet, José M Mato, Urko M Marigorta\",\"doi\":\"10.1038/s41525-025-00491-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Precision medicine requires biomarkers that stratify patients and improve clinical outcomes. Although longitudinal multi-omic analyses provide insights into pathological states, their utility in stratifying healthy individuals remains underexplored. We performed a cross-sectional integrative study of three omic layers, including genomics, urine metabolomics, and serum metabolomics/lipoproteomics, on a cohort of 162 individuals without pathological manifestations. We studied each omic layer separately and after integration, concluding that multi-omic integration provides optimal stratification capacity. We identified four subgroups and, for a subset of 61 individuals, longitudinal data for two additional time-points allowed us to evaluate the temporal stability of the molecular profiles of each identified subgroup. Additional functional annotation uncovered accumulation of risk factors associated with dyslipoproteinemias in one subgroup, suggesting targeted monitoring could reduce future cardiovascular risks. Overall, our methodology uncovers the potential of multi-omic profiling to serve as a framework for precision medicine aimed at early prevention strategies.</p>\",\"PeriodicalId\":19273,\"journal\":{\"name\":\"NPJ Genomic Medicine\",\"volume\":\"10 1\",\"pages\":\"35\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-05-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12049560/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NPJ Genomic Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41525-025-00491-7\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GENETICS & HEREDITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Genomic Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41525-025-00491-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
Multi-omic integration sets the path for early prevention strategies on healthy individuals.
Precision medicine requires biomarkers that stratify patients and improve clinical outcomes. Although longitudinal multi-omic analyses provide insights into pathological states, their utility in stratifying healthy individuals remains underexplored. We performed a cross-sectional integrative study of three omic layers, including genomics, urine metabolomics, and serum metabolomics/lipoproteomics, on a cohort of 162 individuals without pathological manifestations. We studied each omic layer separately and after integration, concluding that multi-omic integration provides optimal stratification capacity. We identified four subgroups and, for a subset of 61 individuals, longitudinal data for two additional time-points allowed us to evaluate the temporal stability of the molecular profiles of each identified subgroup. Additional functional annotation uncovered accumulation of risk factors associated with dyslipoproteinemias in one subgroup, suggesting targeted monitoring could reduce future cardiovascular risks. Overall, our methodology uncovers the potential of multi-omic profiling to serve as a framework for precision medicine aimed at early prevention strategies.
NPJ Genomic MedicineBiochemistry, Genetics and Molecular Biology-Molecular Biology
CiteScore
9.40
自引率
1.90%
发文量
67
审稿时长
17 weeks
期刊介绍:
npj Genomic Medicine is an international, peer-reviewed journal dedicated to publishing the most important scientific advances in all aspects of genomics and its application in the practice of medicine.
The journal defines genomic medicine as "diagnosis, prognosis, prevention and/or treatment of disease and disorders of the mind and body, using approaches informed or enabled by knowledge of the genome and the molecules it encodes." Relevant and high-impact papers that encompass studies of individuals, families, or populations are considered for publication. An emphasis will include coupling detailed phenotype and genome sequencing information, both enabled by new technologies and informatics, to delineate the underlying aetiology of disease. Clinical recommendations and/or guidelines of how that data should be used in the clinical management of those patients in the study, and others, are also encouraged.